Ocugen, Inc.
OCGN Healthcare Biotechnology
Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024. In the quarter to June 2026, revenue grew 8.38%, EPS fell 40.0%, free cash flow fell 13.4% and total debt fell 93.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OCGN
Ocugen, Inc. (OCGN) EV/Sales
As of 16 October 2026, Ocugen, Inc. (OCGN) trades at a EV/Sales of 36.2×. Over the past ten years it has ranged from 0.0× (June 2023) to 171× (March 2026); the current reading is higher than 78% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 94.1× | 101.28% |
| FY2024 | 46.8× | 124.29% |
| FY2023 | 20.9× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 91.7× | (30.64%) |
| Mar 2026 | 132× | 40.41% |
| Dec 2025 | 94.1× | 2.61% |
| Sep 2025 | 91.7× | 52.70% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | −0.5× |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 1.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| PRLD Prelude Therapeutics Incorporated compare | 7.5× |
| OCGN Ocugen, Inc. | 36.2× |
| EYPT EyePoint, Inc. compare | 40.8× |
| PALI Palisade Bio, Inc. compare | 230× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)